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cations	 (OR	=	6.07;	 P	=	0.01),	 and	 also	 with	 architecture	 complexity	 (OR	=	2.06;	
P	=	0.02).	Using	the	WHO	classification,	Bcl‐2	loss	showed	low	diagnostic	accuracy	in	
detecting	premalignant	hyperplasia	(area	under	the	curve	[AUC]	=	0.708),	with	a	sensi-
tivity	of	0.41,	a	 specificity	of	0.81,	a	positive	 likelihood	 ratio	of	3.22,	and	a	negative	
likelihood	ratio	of	0.69.	Using	the	EIN	classification,	accuracy	was	high	(AUC	=	0.938),	





















ture,	 included	 in	 the	 former	 classification	 (WHO,	 1994),	 has	 been	
excluded,	 although	 it	 appears	 to	be	 associated	with	higher	 risk	of	
progression	to	endometrial	cancer.1-3
The	 EIN	 system	 differentiates	 between	 premalignant	 EIN	 and	
benign	 endometrial	 hyperplasia	 based	 on	 the	 presence	 of	 three	
morphological	 parameters	 (glands	 exceeding	 stroma,	 lesion	 size	









A	 great	 number	 of	 immunohistochemical	 markers	 have	 been	
studied	to	improve	the	reliability	of	the	diagnosis.	The	anti‐apoptotic	
protein	B‐cell	lymphoma	2	(Bcl‐2)	is	upregulated	through	the	actions	
of	 estrogens	 and	 its	 expression	 has	 been	 observed	 to	 increase	 in	
proliferative	 endometrium	 and	 in	 benign	 endometrial	 hyperplasia.	
Several	studies	have	found	a	 loss	of	Bcl‐2	expression	in	neoplastic	
endometrial	 samples	 (premalignant	 endometrial	 hyperplasia	 and	
endometrial	cancer).8,9	Therefore,	Bcl‐2	 loss	has	been	proposed	as	
a	 marker	 to	 detect	 intraepithelial	 neoplasia	 in	 endometrial	 speci-
mens.10However	the	role	of	Bcl‐2	loss	of	expression	in	endometrial	




chemical	 expression	 in	 histological	 specimens	 of	 proliferative	 endo-























lymphoma	2	 (Bcl‐2)	 loss	 is	 a	 highly	 specific	 and	 accurate	
marker	of	endometrial	precancer.	Bcl‐2	loss	in	endometrial	
hyperplasia	may	be	a	novel	indication	for	treatment.
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ing	 the	 immunohistochemical	 expression	 of	 Bcl‐2	 on	 histological	







(vii)	 endometrial	 hyperplasia	 data	 overlapping	 with	 an	 already	 in-
cluded	study.





























unpublished	 data	 regarding	 Bcl‐2	 expression	 in	 benign	 endometrial	
hyperplasia.12






hyperplasia	 according	 to	 the	EIN	 classification;	 premalignant	 en-
dometrial	 hyperplasia	 included	 atypical	 endometrial	 hyperplasia	
according	to	the	WHO	classification	or	EIN	according	to	the	EIN	
classification.	 Regarding	 benign	 and	 premalignant	 endometrial	





























sensitivity,	specificity,	positive	 likelihood	ratio	 (LR+),	and	negative	 likeli-
hood	ratio	(LR−)	with	95%	CI.	The	area	under	the	curve	(AUC)	was	cal-
culated	on	summary	receiver	operating	characteristic	curves.	Diagnostic	
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accuracy	was	considered	absent	for	AUC	≤	0.5,	low	for	0.5	<	AUC	≤	0.75,	
moderate	for	0.75	<	AUC	≤	0.9,	high	for	0.9	<	AUC	<	0.97,	and	very	high	
for	AUC	≥	0.97.	A	 random	effect	model	was	 planned	 previously,	 since	
a	 significant	 heterogeneity	 is	 expected	 in	meta‐analyses	 of	 diagnostic	
accuracy.13
Where	possible,	we	assessed	whether	 the	diagnostic	 accuracy	



















sity	 of	 staining,	 three	 assessed	 the	 rate	 of	 stained	 cells,	while	 six	
used	more	than	one	parameter.	Out	of	five	studies	using	a	combined	






For	 the	patients’	 selection	domain,	 three	 studies	were	 considered	









they	 considered	 only	 one	 parameter).	 For	 the	 reference	 standard	








3.1 | B‐cell lymphoma 2 expression and 
histological diagnosis
B‐cell	 lymphoma	2	 loss	was	not	significantly	more	common	 in	be-









•	 when	 the	 EIN	 system	 was	 adopted,	 the	 OR	 was	 6.07	 (95%	 CI	
1.50‐24.56;	P	=	0.01),	with	no	heterogeneity	(I2 =	0%)	(Figure	3c).
The	difference	between	WHO	and	EIN	groups	was	not	significant	
(chi‐squared = 0.18; P	value	=	0.67)	(Figure	3c).
B‐cell	 lymphoma	 2	 was	 also	 significantly	 associated	 with	 the	
complexity	of	glandular	 architecture,	with	an	OR	of	2.06	 (95%	CI,	
1.13‐3.74;	 P	 value	 of	 0.02)	 and	 without	 heterogeneity	 (I2 =	0%).	




F I G U R E  1  Flow	diagram	of	studies	identified	in	the	systematic	
review	using	Preferred	Reporting	Item	for	Systematic	Reviews	and	
Meta‐analyses]	template.	Bcl‐2,	B‐cell	lymphoma	2
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accuracy	 for	 a	 complete	 loss	of	 expression	and	 for	 three	differ-
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CI,	 1.46‐18.40)	 and	 0.86	 (95%	 CI,	 0.75‐1.00),	 respectively.	 The	






















respectively.	 Heterogeneity	 was	 absent	 for	 sensitivity	 (I2 =	0%),	
insignificant	for	specificity	(I2 =	2.9%)	and	LR+	(I2 =	24.7%),	low	for	
LR−	(I2 =	30.3%).
For	 threshold	 III	 (weak	 intensity	 in	 >	67%	 cells,	 moderate	
intensity	 in	 33%‐67%	 cells,	 or	 strong	 intensity	 in	 ≤	33%	 cells),	
sensitivity	 and	 specificity	 were	 0.47	 (95%	 CI,	 0.21‐2.82)	 and	
0.44	 (95%	CI	0.32‐0.57),	 respectively,	with	LR+	and	LR−	of	0.78	








cant	 differences	 were	 found	 between	 proliferative	 endometrium	
and	 benign	 endometrial	 hyperplasia,	 and	 between	 premalignant	
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endometrial	 hyperplasia	 and	 endometrial	 cancer.	 These	 findings	









Bcl‐2	 loss	 is	 a	marker	of	precancer,	 such	 results	 suggest	 that	 the	
EIN	criteria	 are	more	 reliable	 than	 the	WHO	criteria.	This	obser-
vation	 is	 in	agreement	with	several	 findings	 reported	 in	 the	 liter-
ature,	 supporting	 the	 view	 that	 the	EIN	 system	 is	more	 accurate	
than	 the	WHO	 system	 in	 predicting	 progression	 to	 endometrial	
cancer.2,3,6	However,	the	difference	between	the	OR	found	in	the	














atypical	 endometrial	 hyperplasia,	 complex	 endometrial	 hyperpla-
sia	progresses	to	cancer	more	frequently	than	simple	endometrial	
hyperplasia.32	 Furthermore,	 Baak	 et	 al.	 reported	 similar	 rates	 of	
progression	between	complex	and	simple	atypical	endometrial	hy-
perplasia,	 showing	 that	 the	EIN	system	classifies	as	premalignant	
a	 considerable	 percentage	 of	 complex	 non‐atypical	 endometrial	
hyperplasias.6
As	 a	 diagnostic	 marker	 in	 the	 differential	 diagnosis	 between	
benign	 and	 premalignant	 endometrial	 hyperplasia	 the	 accuracy	 of	
Bcl‐2	 appears	 to	 vary	 according	 to	 the	 classification	 system	 ad-










However,	 independent	 of	 the	 classification	 adopted,	 the	 sen-
sitivity	was	low,	indicating	that	only	a	minor	percentage	of	prema-
lignant	endometrial	hyperplasia	shows	the	loss	of	Bcl‐2	expression.	
Such	 limits	cannot	be	overcome,	even	by	 increasing	 the	 threshold	
of	 Bcl‐2	 expression	 to	 be	 considered.	 As	 the	 threshold	 increases,	
sensitivity	 improves	 slightly	 (complete	 loss:	 0.18→threshold	 I:	
0.18→threshold	 II:	 0.26→threshold	 III:	 0.44),	 but	 specificity	 dra-
matically	 worsens	 (0.97→0.91	→	0.76→0.44),	 as	 well	 as	 the	 LR+	
(5.16→1.88→1.11→0.78)	 and	 the	 LR−	 (0.86→0.91→0.98→1.26).	
This	 makes	 immunohistochemistry	 for	 Bcl‐2	 inadequate	 as	 a	
stand‐alone	 test	 in	 the	 routine	diagnosis	of	endometrial	hyperpla-
sia,	since	many	patients	at	risk	of	progression	would	be	missed.	On	
the	other	hand,	 the	specificity	of	Bcl‐2	 loss	 for	 the	EIN	criteria	of	
premalignancy	appeared	excellent.	Thus,	Bcl‐2	 loss	 in	endometrial	
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hyperplasia	 should	 be	 considered	 to	 be	 strongly	 indicative	 of	 the	
neoplastic	process.	When	the	premalignant	features	in	endometrial	
hyperplasia	are	ambiguous	the	finding	of	Bcl‐2	loss	may	still	indicate	





that	 assessed	 Bcl‐2	 as	 a	 marker	 of	 the	 progression	 of	 endometrial	













To	 the	 best	 of	 our	 knowledge,	 this	 study	 may	 be	 the	 first	
meta‐analysis	 assessing	 the	 expression	 of	 Bcl‐2	 in	 endometrial	
hyperplasia.	We	 defined	 the	 association	 of	 Bcl‐2	 loss	with	 the	
neoplastic	nature	of	endometrial	hyperplasia,	and	 the	accuracy	
of	 immunohistochemistry	 for	 Bcl‐2	 in	 a	 differential	 diagnosis	







tics	of	 the	patients	 (such	as	 age	and	body	mass	 index)	 and	 the	
type	of	sample	(such	as	hysteroscopic	biopsy,	curettage,	or	sur-
gical	 specimen).	 The	 selection	 criteria	 for	 participants	 differed	
among	 the	 studies,	 and	 in	most	 cases	 they	were	 not	 specified	
(Figure	2).	Further	 studies	 in	 this	 field	 should	 include	consecu-
tive	patients	to	avoid	spectrum	bias.
Histological	 slides	 were	 reviewed	 simultaneously	 by	 at	 least	
two	pathologists	 in	fewer	than	50%	of	the	included	studies,	creat-
ing	 a	 possible	 bias	 in	 the	 reference	 standard	 (Figure	 2).	However,	
statistical	heterogeneity	among	studies	was	 low	or	absent	 in	most	
of	 our	 analyses,	 giving	 solidity	 to	 our	 results.	 High	 heterogeneity	
was	observed	only	for	the	diagnostic	accuracy	analysis,	where	it	is	
expected.13
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